With these results in mind, therapeutic strategies to upregulate CD200 signaling may be effective in treating EGFR-mutant NSCLC tumors by re-sensitizing them to gefitinib and potentially overcoming EGFR-TKI resistance. This evidence concerns the gene CD200 and non-small cell lung carcinoma.